The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Györy, I.
Right arrow Articles by Wright, K. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Györy, I.
Right arrow Articles by Wright, K. L.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Protein
*UniGene
*Substance via MeSH
The Journal of Immunology, 2003, 170: 3125-3133.
Copyright © 2003 by The American Association of Immunologists

Identification of a Functionally Impaired Positive Regulatory Domain I Binding Factor 1 Transcription Repressor in Myeloma Cell Lines1

Ildikó Györy*, György Fejér2,*, Nilanjan Ghosh*, Ed Seto* and Kenneth L. Wright3,*,{dagger}

* H. Lee Moffitt Cancer Center and Research Institute, Department of Interdisciplinary Oncology and {dagger} Department of Biochemistry and Molecular Biology, University of South Florida, Tampa, FL 33612

B cell differentiation into a plasma cell requires expression of the positive regulatory domain zinc finger protein 1 gene (PRDM1) that encodes the positive regulatory domain I binding factor 1 (PRDI-BF1 or Blimp-1) protein. It represses the transcription of specific target genes, including c-myc, the MHC class II trans-activator, Pax-5, and CD23b. In this study we demonstrate the presence of an alternative protein product of the PRDM1 gene. The new protein, PRDI-BF1{beta}, has a disrupted PR domain and lacks the amino-terminal 101 aa of the originally described protein. PRDI-BF1{beta} has a dramatic loss of repressive function on multiple target genes, but maintains normal DNA-binding activity, nuclear localization, and association with histone deacetylases and deacetylase activity. Myeloma cell lines express the highest levels of PRDM1{beta} mRNA relative to the full-length form, while primary cells and several other cell lines have very low, but detectable, levels of PRDM1{beta}. RNA analysis and analysis of the PRDM1 promoters demonstrate that PRDI-BF1{beta} is generated from the same gene by alternative transcription initiation using an internal promoter. These newly described features of the PRDM1 gene are highly analogous to the PRDM2 (RIZ) and PRDM3 (MDS1-EVI1) genes, in which each express a truncated protein missing the PR domain. The expression of each of the truncated proteins is elevated in cancerous cells and may play an important role in the disease.




This article has been cited by other articles:


Home page
BloodHome page
K. D'Costa, D. Emslie, D. Metcalf, G. K. Smyth, A. Karnowski, A. Kallies, S. L. Nutt, and L. M. Corcoran
Blimp1 is limiting for transformation in a mouse plasmacytoma model
Blood, June 4, 2009; 113(23): 5911 - 5919.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
K. Nie, M. Gomez, P. Landgraf, J.-F. Garcia, Y. Liu, L. H.C. Tan, A. Chadburn, T. Tuschl, D. M. Knowles, and W. Tam
MicroRNA-Mediated Down-Regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg Cells: A Potential Pathogenetic Lesion in Hodgkin Lymphomas
Am. J. Pathol., July 1, 2008; 173(1): 242 - 252.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W.-L. Zhao, Y.-Y. Liu, Q.-L. Zhang, L. Wang, C. Leboeuf, Y.-W. Zhang, J. Ma, J.-F. Garcia, Y.-P. Song, J.-M. Li, et al.
PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor
Blood, April 1, 2008; 111(7): 3867 - 3871.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. Tam, M. Gomez, and K. Nie
Significance of PRDM1{beta} expression as a prognostic marker in diffuse large B-cell lymphomas
Blood, February 15, 2008; 111(4): 2488 - 2489.
[Full Text] [PDF]


Home page
DevelopmentHome page
E. J. Robertson, I. Charatsi, C. J. Joyner, C. H. Koonce, M. Morgan, A. Islam, C. Paterson, E. Lejsek, S. J. Arnold, A. Kallies, et al.
Blimp1 regulates development of the posterior forelimb, caudal pharyngeal arches, heart and sensory vibrissae in mice
Development, December 15, 2007; 134(24): 4335 - 4345.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y.-Y. Liu, C. Leboeuf, J.-Y. Shi, J.-M. Li, L. Wang, Y. Shen, J.-F. Garcia, Z.-X. Shen, Z. Chen, A. Janin, et al.
Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma
Blood, July 1, 2007; 110(1): 339 - 344.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. Tam, M. Gomez, A. Chadburn, J. W. Lee, W. C. Chan, and D. M. Knowles
Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas
Blood, May 15, 2006; 107(10): 4090 - 4100.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
C. A. Davis, M. Haberland, M. A. Arnold, L. B. Sutherland, O. G. McDonald, J. A. Richardson, G. Childs, S. Harris, G. K. Owens, and E. N. Olson
PRISM/PRDM6, a Transcriptional Repressor That Promotes the Proliferative Gene Program in Smooth Muscle Cells.
Mol. Cell. Biol., April 1, 2006; 26(7): 2626 - 2636.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
L. Pasqualucci, M. Compagno, J. Houldsworth, S. Monti, A. Grunn, S. V. Nandula, J. C. Aster, V. V. Murty, M. A. Shipp, and R. Dalla-Favera
Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.
J. Exp. Med., February 20, 2006; 203(2): 311 - 317.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Tunyaplin, A. L. Shaffer, C. D. Angelin-Duclos, X. Yu, L. M. Staudt, and K. L. Calame
Direct Repression of prdm1 by Bcl-6 Inhibits Plasmacytic Differentiation
J. Immunol., July 15, 2004; 173(2): 1158 - 1165.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2003 by The American Association of Immunologists, Inc. All rights reserved.